230 related articles for article (PubMed ID: 28805609)
1. Efficacy of PET/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI.
Kusunoki S; Terao Y; Ujihira T; Fujino K; Kaneda H; Kimura M; Ota T; Takeda S
Taiwan J Obstet Gynecol; 2017 Aug; 56(4):508-513. PubMed ID: 28805609
[TBL] [Abstract][Full Text] [Related]
2. A multiparametric MRI-based machine learning to distinguish between uterine sarcoma and benign leiomyoma: comparison with
Nakagawa M; Nakaura T; Namimoto T; Iyama Y; Kidoh M; Hirata K; Nagayama Y; Oda S; Sakamoto F; Shiraishi S; Yamashita Y
Clin Radiol; 2019 Feb; 74(2):167.e1-167.e7. PubMed ID: 30471748
[TBL] [Abstract][Full Text] [Related]
3. Assessment of intratumor heterogeneity in mesenchymal uterine tumor by an
Tsujikawa T; Yamamoto M; Shono K; Yamada S; Tsuyoshi H; Kiyono Y; Kimura H; Okazawa H; Yoshida Y
Ann Nucl Med; 2017 Dec; 31(10):752-757. PubMed ID: 28905201
[TBL] [Abstract][Full Text] [Related]
4. Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET.
Yoshida Y; Kiyono Y; Tsujikawa T; Kurokawa T; Okazawa H; Kotsuji F
Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1824-31. PubMed ID: 21656049
[TBL] [Abstract][Full Text] [Related]
5. Investigating the diagnostic value of quantitative parameters based on T2-weighted and contrast-enhanced MRI with psoas muscle and outer myometrium as internal references for differentiating uterine sarcomas from leiomyomas at 3T MRI.
Malek M; Rahmani M; Seyyed Ebrahimi SM; Tabibian E; Alidoosti A; Rahimifar P; Akhavan S; Gandomkar Z
Cancer Imaging; 2019 Apr; 19(1):20. PubMed ID: 30935419
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of preoperative ¹⁸F-FDG PET/CT in uterine leiomyosarcoma.
Park JY; Lee JW; Lee HJ; Lee JJ; Moon SH; Kang SY; Cheon GJ; Chung HH
J Gynecol Oncol; 2017 May; 28(3):e28. PubMed ID: 28382795
[TBL] [Abstract][Full Text] [Related]
7. Case of uterine leiomyoma showing fludeoxyglucose uptake on F-18 fludeoxyglucose positron emission tomography/computed tomography.
Park JH; Han JY; Hyun IY; Lee BI; Moon YS
J Obstet Gynaecol Res; 2010 Dec; 36(6):1261-4. PubMed ID: 21083837
[TBL] [Abstract][Full Text] [Related]
8. Role of
Albano D; Zizioli V; Treglia G; Odicino F; Giubbini R; Bertagna F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):10-16. PubMed ID: 30396849
[TBL] [Abstract][Full Text] [Related]
9. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
10. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging.
Sharma P; Kumar R; Singh H; Jeph S; Sharma JB; Jain SK; Sharma DN; Bal C; Malhotra A
Nucl Med Commun; 2012 Feb; 33(2):185-90. PubMed ID: 22107993
[TBL] [Abstract][Full Text] [Related]
11. Utility of Clinical Parameters and Multiparametric MRI as Predictive Factors for Differentiating Uterine Sarcoma From Atypical Leiomyoma.
Bi Q; Xiao Z; Lv F; Liu Y; Zou C; Shen Y
Acad Radiol; 2018 Aug; 25(8):993-1002. PubMed ID: 29422425
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of FDG PET/CT findings of uterine tumors.
Kitajima K; Murakami K; Kaji Y; Sugimura K
AJR Am J Roentgenol; 2010 Sep; 195(3):737-43. PubMed ID: 20729454
[TBL] [Abstract][Full Text] [Related]
13. Standardized uptake values of uterine leiomyoma with 18F-FDG PET/CT: variation with age, size, degeneration, and contrast enhancement on MRI.
Kitajima K; Murakami K; Yamasaki E; Kaji Y; Sugimura K
Ann Nucl Med; 2008 Jul; 22(6):505-12. PubMed ID: 18670857
[TBL] [Abstract][Full Text] [Related]
14. High metabolic characteristics of uterine fibroids in 18F-FDG PET/CT imaging and the underlying mechanisms.
Ma Y; Shao X; Shao X; Wang X; Wang Y
Nucl Med Commun; 2016 Nov; 37(11):1206-11. PubMed ID: 27281358
[TBL] [Abstract][Full Text] [Related]
15. Analysis of positron emission tomography/computed tomography in patients to differentiate between malignant transformation of endometrioma and endometrioma.
Kusunoki S; Ota T; Kaneda H; Kimura M; Terao Y; Takeda S
Int J Clin Oncol; 2016 Dec; 21(6):1136-1141. PubMed ID: 27380167
[TBL] [Abstract][Full Text] [Related]
16. Soft Tissue Sarcoma Response to Two Cycles of Neoadjuvant Chemotherapy: A Multireader Analysis of MRI Findings and Agreement with RECIST Criteria and Change in SUVmax.
Favinger JL; Hippe DS; Davidson DJ; Elojeimy S; Roth ES; Lindberg AW; Ha AS
Acad Radiol; 2018 Apr; 25(4):470-475. PubMed ID: 29273189
[TBL] [Abstract][Full Text] [Related]
17. Standardized uptake value and metabolic tumor volume measured by ¹⁸F FDG PET/CT are sensitive biomarkers for the presence of lymph node metastasis in patients with cervical carcinoma.
Vural GU; Akkas BE; Demirel BB
Rev Esp Med Nucl Imagen Mol; 2014; 33(5):268-73. PubMed ID: 25018135
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer.
Park JY; Kim EN; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2008 Mar; 108(3):486-92. PubMed ID: 18201753
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment tumor SUV
Ha SC; Oh JS; Roh JL; Moon H; Kim JS; Cho KJ; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):33-40. PubMed ID: 27448574
[TBL] [Abstract][Full Text] [Related]
20. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer.
Kim HJ; Cho A; Yun M; Kim YT; Kang WJ
Ann Nucl Med; 2016 Feb; 30(2):104-13. PubMed ID: 26546334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]